ONC · NASDAQ
BeOne Medicines Ltd.
$377.63 -4.75 (-1.24%)
Company overview
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with operations spanning over 45 countries across six continents, the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Exchange
- NASDAQ
- Market cap
- $40.4B
- Employees
- 11,000
- Website
- beonemedicines.com
- CEO
- John V. Oyler
- Listed
- February 2, 2016
- P/E
- 7.57
- Dividend yield
- 0.00%
Company financials
- Revenue
- $5.7B
- Gross profit
- $5.1B
- Operating income
- $686M
- EBITDA
- $906M
- Net income
- $513M
- EPS
- $49.88
- Total assets
- $8.6B
- Total debt
- $1.1B
- Gross margin
- 88.31%
- Net margin
- 8.94%
- Earnings yield
- 13.21%
Showing FY 2025
ONC
1D
NASDAQ
O378.06H384.81L375.52C382.27-4.19 (-1.08%)Vol359.35K